PHOSPHOTEC
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Oct 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOSPHOTEC is an injectable diagnostic or therapeutic agent approved by Bracco in 1976 as an NDA. The specific mechanism of action and clinical indications are not publicly detailed in available data. Based on the brand name and formulation, it likely involves phosphate-based chemistry for imaging or metabolic applications.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting defensive positioning and likely smaller, maintenance-focused commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PHOSPHOTEC currently has zero linked job openings, reflecting its mature, low-growth status. Careers on this product focus on defending market share and managing decline rather than innovation or expansion.
Brand ManagerField Sales Representative
Worked on PHOSPHOTEC at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.